Aquestive (AQST) CPO Peter Boyd Exercises Warrants for 2,293 Shares

What Happened Peter E. Boyd, Chief People Officer of Aquestive Therapeutics (AQST), exercised a common stock purchase warrant on 2026-09-09 to acquire 2,293 shares at an exercise price of $0.96 per share, paying $2,201 in cash. The filing also reports the corresponding disposition of the derivative (the warrant) for $0.00, reflecting that the warrant was cancelled upon exercise. This was a purchase (exercise of a warrant), not an open-market sale.

Key Details

• Transaction date: 2026-09-09; Filing date: 2026-09-10 (timely)
• Shares acquired: 2,293 at $0.96 each; total cash paid: $2,201
• Derivative disposed: 2,293 warrants reported at $0.00 (warrant cancelled on exercise)
• Shares owned after the transaction: Not disclosed in the filing
• Footnote: Warrant issued June 8, 2022; became exercisable Dec 8, 2022; expires June 8, 2027; exercise price $0.96/share
• Transaction type: Exercise of an in‑the‑money derivative (cash exercise of a warrant)

Context This was a cash exercise of a previously issued warrant (not a cashless/automatic sale). The $0.00 "disposed" entry reflects the surrender/cancellation of the warrant upon exercise. Such exercises are common ways insiders convert instruments into stock; they do not by themselves indicate a view on the company’s near‑term stock direction.